company background image
APS logo

Aptose Biosciences TSX:APS Stock Report

Last Price

CA$2.24

Market Cap

CA$32.2m

7D

6.2%

1Y

-82.2%

Updated

28 Mar, 2024

Data

Company Financials +

APS Stock Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.

APS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Aptose Biosciences Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aptose Biosciences
Historical stock prices
Current Share PriceCA$2.24
52 Week HighCA$13.35
52 Week LowCA$1.85
Beta1.44
1 Month Change-12.84%
3 Month Change-33.13%
1 Year Change-82.22%
3 Year Change-98.01%
5 Year Change-94.23%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation

Mar 26
Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Dec 08
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aug 05
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

Apr 02
We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Sep 30
Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Feb 07
Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Jan 03
Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Nov 29
We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares

Jul 11
Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Jun 27
Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Shareholder Returns

APSCA BiotechsCA Market
7D6.2%1.4%0.4%
1Y-82.2%-26.0%9.0%

Return vs Industry: APS underperformed the Canadian Biotechs industry which returned -26% over the past year.

Return vs Market: APS underperformed the Canadian Market which returned 9% over the past year.

Price Volatility

Is APS's price volatile compared to industry and market?
APS volatility
APS Average Weekly Movement9.0%
Biotechs Industry Average Movement12.4%
Market Average Movement8.5%
10% most volatile stocks in CA Market18.4%
10% least volatile stocks in CA Market3.1%

Stable Share Price: APS's share price has been volatile over the past 3 months.

Volatility Over Time: APS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198636William Ricehttps://www.aptose.com

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS.

Aptose Biosciences Inc. Fundamentals Summary

How do Aptose Biosciences's earnings and revenue compare to its market cap?
APS fundamental statistics
Market capCA$32.22m
Earnings (TTM)-CA$69.36m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$51.21m
Earnings-US$51.21m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.26
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did APS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.